Anuh Pharma DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025


0.73×	0.76×	0.78×
1.11×	1.08×	1.17×
7.6%	6.5%	7.9%
1.45×	1.45×	1.31×
1.54×	1.58×	1.55×
13.7%	12.2%	14.6%
12.1%	12.1%	14.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

ANUHPHR₹77.05

Anuh Pharma Limited

· Pharma & Health

₹ CrorePeersAHCL WANBURY ZIMLAB BAJAJHCARE THEMISMED LINCOLN VALIANTLAB SIGACHIMcap ₹772 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.78	0.76	0.73
Interest Burden (Pretax/EBIT) ×	1.17	1.08	1.11
EBIT Margin %	7.89	6.52	7.58
Asset Turnover ×	1.31	1.45	1.45
Financial Leverage (Assets/Equity) ×	1.55	1.58	1.54
ROE (5-step product, year-end total equity) %	14.57	12.21	13.69
ROE (owners' profit / average owners' equity) %	14.52	12.10	12.10

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.